Intervention

Amlodipine/Atorvastatin

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 3 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting0

Common conditions5

Lead sponsors shown1

Clinical trials

3 shown

Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)NCT01107743 · 2010-06-01

COMPLETED

Open Label Study Assessing Effectiveness Of Amlodipine/Atorvastatin In Subjects With Hypertension and DyslipidaemiaNCT00330785 · 2004-10-01

COMPLETED

Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient PopulationNCT00150384 · 2004-07-01

COMPLETED

Common conditions

Hypertension3 Dyslipidemia2 Angina Pectoris1 Familial Hypercholesterolemia1 Hypercholesterolemia1

Leading sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. 3

Trial status mix

COMPLETED3

Phase mix

PHASE31

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.